To investigate the therapeutic impact of dulaglutide on preventing peritoneal dialysis dysfunction: a randomized, open-Label, controlled clinical trial and animal model

Chang Gung Memorial Hospital0 个研究点目标入组 75 人开始时间: 2022年10月26日最近更新: 2022年11月7日

试验速览

暂无简介。

•1. CKD with a clinical cause of diabetes mellitus
•2. Age is = 20 and= 75 years
•3. The subject had been receiving peritoneal dialysis for more than 3 months.
•4. The subject treat with or without OHAs or insulin treatment
•5. The subject doesn’t treated with GLP-1 analogue
•6. The subject is able and willing to return for required follow-up visits and examinations.

•1. Female participants who are pregnant or breastfeeding
•2. Participants who have any of the following medical conditions:
•2.1. Chronic inflammatory or autoimmune diseases
•2.2. Viral Hepatitis B or C liver infection, liver cirrhosis, or significant liver disease
•2.3. CKD from causes other than diabetes
•2.4. Cancer (malignancy)
•2.5. Febrile illnesses
•2.6. Age is < 20 or >75 years
•2.7. The subject has a life expectancy of less than one years.
•2.8. The subject has allergic reaction to any GLP-1 analogues.
•2.9. HIV infection- the virus that causes AIDS
•2.10. The subject is deemed by study physicians to be unsuitable for enrollment.
•2.11. The subject is currently enrolled in another investigational study or registry that would directly/indirectly interfere with the current study.
•2.12. The subject is unable or unwilling to return for required follow-up and examination.

发起方

Chang Gung Memorial Hospital